Antiviral Compounds Targeting HCV Genotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) therapeutic agents have limited effectiveness due to toxicity and side effects, and there is a need for broad-spectrum agents that are less susceptible to viral resistance, particularly against HCV genotypes 1a, 1b, 2a, 3a, and 4a.
Innovation Solution
A compound of formula (I) is developed, comprising specific structural elements such as E1a-V1a—C(═O)—P1a—W1a—P1b—C(═O)—V1b-E1b, where various substituents and functional groups are defined, forming a molecular structure designed to target HCV effectively while minimizing resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HCV therapeutic agents are used, then liver disease treatment is achieved, but toxicity and side effects occur that limit usefulness
Solution Approach 1:
The patent modifies chemical parameters of HCV inhibitors by introducing specific substituent groups (E1a, E1b, V1a, V1b, P1a, P1b, W1a) at defined positions in the molecular structure, changing the chemical composition to achieve broad-spectrum activity against multiple HCV genotypes while reducing toxicity and side effects
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional groups and substituent patterns in a single inhibitor molecule, designed to target conserved regions across different HCV genotypes (1a, 1b, 2a, 3a, 4a) simultaneously, achieving broad-spectrum efficacy with improved safety profile
2Reliability
If HCV inhibitors are used, then establishment and progression of infection is limited, but viral resistance develops
Solution Approach 1:
The patent designs inhibitors with multiple substituent configurations (E1a, E1b, V1a, V1b, P1a, P1b, W1a) that can bind to conserved regions across diverse HCV genotypes, creating multi-functional agents that prevent viral replication while reducing the likelihood of resistance mutations emerging
Data Source
AI summary
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.